XM does not provide services to residents of the United States of America.
N
N

Novartis

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss stocks - Factors to watch on November 4

Swiss stocks - Factors to watch on November 4 ZURICH/GDANSK, Nov 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS NOVARTIS AG NOVN.S CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper CRISPR THERAPEUTICS AG CRSP.BN Third quarter results due. ANALYSTS' VIEWS BACHEM HOLDING AG BANB.S - JP MORGAN INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE CHF 86 ECONOMY SNB data on Swiss sight deposits due at 0900 GMT.
N

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper ZURICH, Nov 2 (Reuters) - Novartis NOVN.S expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from the end of patent protection on some drugs.
N

Biogen lifts annual profit forecast as new treatments boost earnings

UPDATE 2-Biogen lifts annual profit forecast as new treatments boost earnings Updates shares, adds analyst comment in paragraph 4, CEO comment in paragraph 7 and graphic By Mariam Sunny Oct 30 (Reuters) - Biogen BIIB.O raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
B
N

Swiss stocks - Factors to watch on October 30

Swiss stocks - Factors to watch on October 30 ZURICH/GDANSK, Oct 30 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: SWISS NATIONAL BANK The Swiss National Bank could further cut interest rates to maintain price stability, Chairman Martin Schlegel said on Tuesday. NOVARTIS NOVN.S Novartis says Scemblix FDA approved in newly diagnosed CML UBS UBSG.S UBS reports $1.4 bln net profit attributable to shareholders in Q3 COMPANY STATEMENTS SANDOZ SDZ.S Nine month
C
K
N
U

Asia Morning Call-Global Markets

UPDATE 1-Asia Morning Call-Global Markets Oct 30 (Reuters) - Stock Markets closing level) Net Chng Stock Markets Net Chng S&P/ASX 200** 8249.2 +27.7 NZX 50** 12783.36 +11.75 DJIA 42233.05 -154.52 NIKKEI** 38903.68 +298.15 Nasdaq 18712.748 +145.559 FTSE** 8219.61 -66.01 S&P 500 5832.92 +9.4 Hang Seng** 20701.14 +101.78 SPI 200 Fut 8268 -7 STI** 3590.36 +6.28 SSEC** 3286.407 -35.7905 KOSPI** 2617.8 +5.37 ---------------------------------------------------------------------------------------- Bonds
A
A
G
N
U
U
J
U
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.